Clinical Trial Update: A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

View source ↗

Summary

A clinical trial evaluating a time-limited use of Ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: CLL, SLL | Status: WITHDRAWN